Improving Patient’s Quality of Life Using a Ceramide-Containing Moisturiser as Monotherapy in Mild to Moderate Atopic Dermatitis

A. Jain, N. Khanna, H. Pandya, K. Chawda, R. Rakshit, N. Balbaki, A. Bitton, A. Kumar

INTRODUCTION & OBJECTIVES

Atopic dermatitis (AD) is associated with altered levels and composition of ceramides which are instrumental in maintaining skin barrier function (SBF), hence their resultant skin barrier dysfunction.¹

Ceramide-containing moisturiser (CCM) was formulated as a multivesicular emulsion (MVE), which is a novel technology consisting of vesicles of oil-in-water emulsion held within another vesicle, ensuring gradual release of active ingredients over time, as vesicles open sequentially (Fig. 1).²

In this study, we evaluated:

• Improvement in patient’s qualityof life
• Reduction in severity of AD
• Restoration of SBF

In 120 Indian patients with mild to moderate AD, when they used a CCM (formulated as an MVE) as monotherapy for 4 weeks.